240 related articles for article (PubMed ID: 27178743)
1. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K; Kalebic T; Cruz C; Faris JE; Ryan DP; Jung J; Wyant T; Fasanmade AA; Messersmith W; Rodon J
Clin Cancer Res; 2016 Oct; 22(20):5049-5057. PubMed ID: 27178743
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K; Wright D; Mercade TM; Van Laethem JL; Gracian AC; Guillen-Ponce C; Faris J; Lopez CM; Hubner RA; Bendell J; Bols A; Feliu J; Starling N; Enzinger P; Mahalingham D; Messersmith W; Yang H; Fasanmade A; Danaee H; Kalebic T
Invest New Drugs; 2017 Oct; 35(5):634-641. PubMed ID: 28527133
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Almhanna K; Miron ML; Wright D; Gracian AC; Hubner RA; Van Laethem JL; López CM; Alsina M; Muñoz FL; Bendell J; Firdaus I; Messersmith W; Ye Z; Fasanmade AA; Danaee H; Kalebic T
Invest New Drugs; 2017 Apr; 35(2):235-241. PubMed ID: 28188407
[TBL] [Abstract][Full Text] [Related]
4. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Kim R; Leal AD; Parikh A; Ryan DP; Wang S; Bahamon B; Gupta N; Moss A; Pye J; Miao H; Inguilizian H; Cleary JM
Cancer Chemother Pharmacol; 2023 Apr; 91(4):291-300. PubMed ID: 36738333
[TBL] [Abstract][Full Text] [Related]
5. TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
Bang YJ; Takano T; Lin CC; Fasanmade A; Yang H; Danaee H; Asato T; Kalebic T; Wang H; Doi T
Cancer Res Treat; 2018 Apr; 50(2):398-404. PubMed ID: 28494535
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.
Coveler AL; Ko AH; Catenacci DV; Von Hoff D; Becerra C; Whiting NC; Yang J; Wolpin B
Invest New Drugs; 2016 Jun; 34(3):319-28. PubMed ID: 26994014
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.
Almhanna K; Prithviraj GK; Veiby P; Kalebic T
Pharmacol Ther; 2017 Feb; 170():8-13. PubMed ID: 27765652
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
11. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
McHugh D; Eisenberger M; Heath EI; Bruce J; Danila DC; Rathkopf DE; Feldman J; Slovin SF; Anand B; Chu R; Lackey J; Reyno L; Antonarakis ES; Morris MJ
Invest New Drugs; 2019 Oct; 37(5):1052-1060. PubMed ID: 30725389
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
17. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
King GT; Eaton KD; Beagle BR; Zopf CJ; Wong GY; Krupka HI; Hua SY; Messersmith WA; El-Khoueiry AB
Invest New Drugs; 2018 Oct; 36(5):836-847. PubMed ID: 29333575
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.
Kuboki Y; Shimizu T; Yonemori K; Kojima T; Kondo S; Koganemaru S; Iwasa S; Harano K; Koyama T; Lu V; Zhou X; Niu H; Yanai T; Garcia-Ribas I; Doi T; Yamamoto N
Cancer Res Commun; 2022 Nov; 2(11):1426-1435. PubMed ID: 36970056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
